NCT01557127 (NEXST) is a clinical trial of Sorafenib (Nexavar, BAY43-9006) in Carcinoma, Renal Cell, sponsored by Bayer.

Who is sponsoring NCT01557127?

NCT01557127 is sponsored by Bayer.

What drugs are being tested in NCT01557127?

Interventions in NCT01557127: Sorafenib (Nexavar, BAY43-9006).

What condition does NCT01557127 study?

NCT01557127 studies Carcinoma, Renal Cell.

Is NCT01557127 still recruiting?

NCT01557127 is currently completed. Last updated 28 March 2017.

Last reviewed 2017-03-28 · How we verify

NCT01557127: NEXST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Completed Last updated 28 March 2017

What this trial tests

trial testing Sorafenib (Nexavar, BAY43-9006) in Carcinoma, Renal Cell in 205 participants. Completed in 31 March 2016.

Timeline

1 November 2011

Primary endpoint
16 May 2014

31 March 2016

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	205
Start date	1 November 2011
Primary completion	16 May 2014
Estimated completion	31 March 2016
Sites	1 location across Poland

Drugs / interventions tested

Sorafenib (Nexavar, BAY43-9006) — full drug profile →

Conditions studied

Carcinoma, Renal Cell — all drugs for Carcinoma, Renal Cell →

Sponsor

Bayer — full company profile →

Who can join

18 and older, any sex, with Carcinoma, Renal Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ferroptosis in Renal Cancer Therapy: A Narrative Review of Drug Candidates.
Yu L, Qiu Y, Tong X. · · 2024 · cited 7× · PMID 39335103 · DOI 10.3390/cancers16183131

Verify or expand the search:

Other trials of Sorafenib (Nexavar, BAY43-9006)

Trials testing the same drug.

NCT05594147 — An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated Wi · completed
NCT03644511 — Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line · terminated
NCT02303444 — An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use o · completed
NCT02185560 — Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Di · active not recruiting
NCT01933945 — Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not E · completed

Other recruiting trials for Carcinoma, Renal Cell

Currently open trials in the same condition.

NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT06222593 — Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant · Phase 1, PHASE2 · recruiting
NCT07166445 — Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT · recruiting
NCT06676527 — Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01557127 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 28 March 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01557127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing